Target Corporation logo

Target Corporation (TGT)

Market Closed
27 Feb, 20:00
NYSE NYSE
$
113. 79
-1
-0.87%
$
53.02B Market Cap
17.63 P/E Ratio
17.07% Div Yield
4,486,442 Volume
5.54 Eps
$ 114.79
Previous Close
Day Range
111.11 113.86
Year Range
83.44 127.06
Want to track TGT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
TGT earnings report is expected in 2 days (3 Mar 2026)
Target Corporation (TGT) Is a Trending Stock: Facts to Know Before Betting on It

Target Corporation (TGT) Is a Trending Stock: Facts to Know Before Betting on It

Target (TGT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 1 year ago
Micron Technology's AI Reach Leads To a BofA Price Target Increase

Micron Technology's AI Reach Leads To a BofA Price Target Increase

Shares of Micron Technology (MU) traded at an intraday record Monday after Bank of America raised its price target, saying the chipmaker will benefit from the booming demand for artificial intelligence (AI) products.

Investopedia | 1 year ago
EV Nickel Provides Update on 2024 Exploration Plan - Initiates Diamond Drill Program on High Grade Target

EV Nickel Provides Update on 2024 Exploration Plan - Initiates Diamond Drill Program on High Grade Target

NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA OR TO US WIRE SERVICES TORONTO, ON / ACCESSWIRE / June 17, 2024 / EV NICKEL INC. (TSX-V:EVNI) ("EVNi" or the "Company") is please to provide an update on its 2024 Exploration Plan and the commencement of diamond drilling on the Langmuir #2, high priority nickel target (see Figure 1).

Accesswire | 1 year ago
New Nvidia Price Target Is Highest on Wall Street

New Nvidia Price Target Is Highest on Wall Street

The chip maker was gaining early Monday as Susquehanna analyst Christopher Rolland became its most bullish advocate.

Barrons | 1 year ago
Target Aims to Reverse Losses With Private-Label Goods, Price Cuts

Target Aims to Reverse Losses With Private-Label Goods, Price Cuts

Target reportedly lost market share in several of its key product categories in the first quarter. The retailer's share shrank in food and household goods, clothing, electronics, homewares and furniture — categories that collectively account for 60% of its revenue, Reuters reported Friday (June 14), citing data from market research firm GlobalData.

Pymnts | 1 year ago
Target Shares Cross Below 200 DMA

Target Shares Cross Below 200 DMA

In trading on Friday, shares of Target crossed below their 200 day moving average of $140.93, changing hands as low as $139.71 per share. Target shares are currently trading down about 3% on the day.

Forbes | 1 year ago
Target (TGT) Hikes Dividend by 1.8%: Key Insights for Investors

Target (TGT) Hikes Dividend by 1.8%: Key Insights for Investors

Target (TGT) increases its quarterly dividend to $1.12 per share, reflecting a 1.8% rise from the previous level and marking the company's 53rd consecutive year of annual dividend growth.

Zacks | 1 year ago
Target (TGT) Could Be a Great Choice

Target (TGT) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Target (TGT) have what it takes?

Zacks | 1 year ago
Cathie Wood, Ark Invest Set New $2,600 Price Target For Tesla: 'Every Car Becomes An AI-Powered Cash Flow Generation Machine'

Cathie Wood, Ark Invest Set New $2,600 Price Target For Tesla: 'Every Car Becomes An AI-Powered Cash Flow Generation Machine'

Ark Invest CEO and founder Cathie Wood may be best known for her 2018 price prediction on Tesla Inc TSLA shares. The price prediction was heavily scrutinized but came true years later and helped boost the profile of Wood and the price of many Ark Invest ETFs.

Benzinga | 1 year ago
Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Agios Pharmaceuticals develops therapies for rare diseases with a focus on Pyruvate Kinase activators like Pyrukynd for PK deficiency. AGIO is advancing its pipeline with research on Mitapivat for thalassemia and sickle cell disease, positioning itself for potential FDA approvals in 2025 and 2026. A $905 million upfront payment from Royalty Pharma is contingent on FDA approval of Vorasidenib by August 2024.

Seekingalpha | 1 year ago
Target raises quarterly dividend by 1.8% to $1.12 a share

Target raises quarterly dividend by 1.8% to $1.12 a share

Target Corp. TGT, -1.57% said Wednesday it's raising its quarterly dividend by 1.8% to $1.12 a share from $1.10 previously. The new dividend is payable Sept.

Marketwatch | 1 year ago
Target, Dick's Sporting Goods facing pushback from investors for 'going woke'

Target, Dick's Sporting Goods facing pushback from investors for 'going woke'

A group of activist investors plans to criticize major retailers Target and Dick's Sporting Goods over "woke" policies at the companies' respective shareholder meetings on Wednesday.

Foxbusiness | 1 year ago
Loading...
Load More